Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Mary Territo, M.D.
Mary Territo, M.D.

Specialty:

Cancer/Medical Oncology
Hematology

General Information:

Gender:
Female
Language(s):
English

Affiliation(s):

Professor, Department of Medicine, Hematology/Oncology
Physician, Department of Medicine, Hematology/Oncology, Bone Marrow/Stem Cell Transplantation Program
Director, Hematopoietic Stem Cell Transplantation
Vice Chair, Academic Affairs, UCLA Department of Medicine
Member, JCCC Cancer and Stem Cell Biology Program Area

Education:

Fellowship:
Hematology/Oncology, Harbor-UCLA Medical Center, 1971 - 1973
Residency:
Internal Medicine, Parkland Memorial Hospital, 1969 - 1971
Internship:
Medicine, Parkland Memorial Hospital, 1968 - 1969
Medical Degree:
M.D., Wayne State University School of Medicine, 1968

Certification(s):

Board Certification(s):
Hematology, American Board of Internal Medicine, 1974
Internal Medicine, American Board of Internal Medicine, 1972

Contact Information:

Phone:
(310) 206-5789 Bone Marrow/Stem Cell Transplantation Program information and referral
(310) 206-6931 or (310) 206-6909 UCLA Oncology Center information and patient appointments
Email:

Practice Information:

Clinical Interest(s):
Bone Marrow Transplantation
Chronic Myelogenous Leukemia
General Hematology
Hematologic Malignancies
Leukemia
Lymphoma
Multiple Myeloma
Myelodysplasia

Scientific Interest(s):

Dr. Mary Territo's clinical research focuses on investigations of treatments and manipulations to improve outcomes in hematologic malignancies and hematopoietic stem cell transplantation. Studies of new antimicrobial agents have identified effective agents to help improve the infectious complications seen in patients with hematologic malignancies and hematopoietic stem cell transplantation. Studies also have looked at the effectiveness of transplantation in different disease settings and in reducing the toxicity seen post-transplantation. Trials are ongoing looking at improving the methodology for transplantation using cord blood as a source of stem cells.

Selected Cancer-Related Publications:

Reddy SM, Winston DJ, Territo MC, Schiller GJ. CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency. Bone Marrow Transplant. 2010 Jun;45(6):979-84. Epub 2010 Mar 1.

Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, Badel K, Calandra G. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant. 2009 Feb;15(2):249-56.

Huynh TN, Weigt SS, Belperio JA, Territo M, Keane MP. Outcome and prognostic indicators of patients with hematopoietic stem cell transplants admitted to the intensive care unit. J Transplant. 2009;2009:917294. Epub 2009 Sep 15.

Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, Huang S, Roskos L, Slavin S, Shadduck RK, Dipersio J, Territo M, Pavletic S, Linker C, Heslop HE, Deeg HJ, Blazar BR, Joachim Deeg H. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood. 2007; 109(6): 2657-62.

Burt RK, Marmont A, Oyama Y, Slavin S, Arnold R, Hiepe F, Fassas A, Snowden J, Schuening F, Myint H, Patel DD, Collier D, Heslop H, Krance R, Statkute L, Verda L, Traynor A, Kozak T, Hintzen RQ, Rose JW, Voltarelli J, Loh Y, Territo M, Cohen BA, Craig RM, Varga J, Barr WG. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens. Arthritis Rheum. 2006; 54(12): 3750-60.